Watchman. What You Need to Know. An in-depth view of the Watchman device with a focus on patient selection and integration into your practice.
|
|
- Chad Baker
- 6 years ago
- Views:
Transcription
1 Watchman What You Need to Know An in-depth view of the Watchman device with a focus on patient selection and integration into your practice. BY SAMEER GAFOOR, MD; LUISA HEUER; JENNIFER FRANKE, MD; MARKUS REINARTZ, MD; STEFAN BERTOG, MD; LAURA VASKELYTE, MD; ILONA HOFMANN, MD; AND HORST SIEVERT, MD The Watchman device (Boston Scientific Corporation) is changing the way we practice stroke prevention or treatment of atrial fibrillation. For the first time, a fully percutaneous intracardiac device has been compared against oral anticoagulation in a randomized controlled trial with a good outcome. How do we select patients? How do we integrate this technology into our practice? This article will endeavor to answer those questions. KEY FEATURES OF THE DEVICE The Watchman device consists of a nitinol frame and a fabric cap. The nitinol structure comes in five available sizes: 21, 24, 27, 30, and 33 mm in diameter. There are 10 fixation anchors around the device perimeter that are used to fix the device into the left atrial appendage (LAA) tissue. The nitinol frame is covered with a polyethylene terephthalate fabric, which acts as a 160-µm filter that prevents emboli from passing through the device (Figure 1). The sheath comes in both double and single anterior curves. The sheath has a 14-F outer diameter (4.7 mm) and a 12-F inner diameter, and it comes in a 75-cm working length. One unique feature of this device is that one sheath is used for all five device sizes. The delivery system consists of a deployment knob connected to a core wire that travels through a hemostasis valve into the sheath (Figure 2). When the device is loaded into the sheath, the markers on the sheath can give a clue as to where the device will land when deployed. The device is loaded to the most distal radiopaque marker band; the three successively proximal marker bands correspond approximately to 21-, 27-, and 33-mm constrained devices, and the spaces between correspond approximately to 24- and 30-mm constrained devices (Figure 3). Figure 1. The Watchman device consists of a nitinol frame covered with a fabric cap. There are 10 fixation anchors, and the fabric cap is a polyethylene terephthalate membrane Boston Scientific Corporation or its affiliates. All JULY/AUGUST 2014 CARDIAC INTERVENTIONS TODAY 77
2 When the device is implanted, it should be checked by four criteria prior to release. The first of these is the position, to make sure that the device does not protrude proximally too far (this should be confirmed in multiple transesophageal views on echocardiography). The second is the anchor pull test, in which the operator gently retracts the deployment knob and releases, observing the device returning to its original position without shift on both fluoroscopy and echocardiography. This confirms that the fixation anchors are engaged. Third is size compression, in which the device is examined for a decrease in measured diameter to between 80% and 92% of the original diameter. Finally, the last test is an evaluation for seal by assessing peridevice leak via atrial angiography and also in multiple echocardiographic views (eg, 0, 45, 90, and 135 ). Together, the position, anchor, size, and seal tests make the mnemonic PASS. PATIENT POPULATION AND SELECTION To understand the possible patient population and selection for the United States, one should understand the patients studied in both the PROTECT-AF 1-3 and the PREVAIL 4 trials. The PROTECT-AF trial was a prospective, randomized (2:1), noninferiority trial of LAA closure versus warfarin in nonvalvular atrial fibrillation patients for prevention of stroke. This was followed by a combined safety analysis of PROTECT-AF and the CAP registry, which showed a decrease in procedural complications with experience. 2 The PREVAIL study was a confirmatory study conducted to provide additional information on the implantation procedure. PREVAIL was a prospective, randomized (2:1) study of the Watchman LAA closure technology compared to warfarin, with inclusion of new centers and new operators to show enhancements to the training program and confirm the late safety rates from PROTECT-AF and CAP. The PROTECT-AF trial included patients with paroxysmal, persistent, or permanent nonvalvular atrial fibrillation, who were all eligible for long-term warfarin therapy. These patients had a CHADS 2 score 1. Exclusion criteria were patients who were contraindicated for aspirin or clopidogrel and had New York Heart Association class IV heart failure, an implanted mechanical valve, an atrial septal or patent foramen ovale device, platelets < 100,000/µL or hemoglobin < 10 g/dl, and patients with a left ventricular ejection fraction of < 30%. PREVAIL had slightly more stringent inclusion criteria, including a CHADS 2 score > 2 or CHADS 2 score = 1 if the patient fulfilled certain criteria (female, aged older than 75 years, baseline left ventricular ejection fraction > 30 and < 35%, years of age Figure 2. Sheath curves and delivery system. The sheath curve can be a double curve (which presents in three dimensions) or a single curve. The delivery system consists of a deployment knob, core wire, and hemostasis valve Boston Scientific Corporation or its affiliates. All with diabetes or coronary artery disease, and 65 years of age or older with documented congestive heart failure). Other probable exclusion criteria are patients with a known other source of emboli (left ventricular thrombus or mobile atheromatous aortic plaque) or a short life expectancy. Of note, the study inclusion criteria of PROTECT-AF is different from patients included in European guidelines, in which interventional, percutaneous LAA closure may be considered in patients with a high stroke risk and contraindications for long-term oral anticoagulation, receiving a IIb rating (level of evidence, B). 5 This guideline was based on the ASAP trial, in which patients who were not candidates for oral anticoagulation safely received the Watchman device with only aspirin and clopidogrel as postprocedural therapy. 6 In the United States, there was a positive US Food and Drug Administration (FDA) panel vote of 13-1 in December Approval is expected soon, with labeling still to be defined. At this point, it is too early to know what the planned patient population and selec- 78 CARDIAC INTERVENTIONS TODAY JULY/AUGUST 2014
3 tion will be in the United States after approval. One can presume that it will be for nonvalvular atrial fibrillation patients with an indication for warfarin but with a reason to seek an alternative treatment to reduce the risk of thromboembolism from the LAA. Because the patient must also qualify based on certain anatomical size limitations of the procedure and device, the patient must also be able to tolerate transesophageal echocardiography (TEE), which is also important to rule out LAA thrombus or other known sources of emboli. IMPACT ON PRACTICE The impact on practice depends on the indication for the device, which is dependent on the FDA indication and CMS coverage decisions. There are more than 5 million people with atrial fibrillation in the United States, and studies have estimated that the overall prevalence is 1% to 2% of the general population. The prevalence of atrial fibrillation is age dependent, with prevalence rates of < 0.5% to 1%, 1% to 4%, and 6% to 15% for ages 50, 65, and 80 years, respectively. Even then, this may be an underestimate, with underdiagnosis due to intermittent atrial fibrillation or intermittently symptomatic atrial fibrillation, especially when estimates are based on studies utilizing electrocardiography at the time of symptoms. 7 Atrial fibrillation is associated with a three- to fivefold increased risk of stroke and accounts for 20% of all strokes. 8 In addition, strokes associated with atrial fibrillation are more recurrent and are often more severe, which utilizes more resources, ends with more disability, and leads to higher mortality compared to the 80% of strokes that occur without atrial fibrillation What is the overall impact of atrial fibrillation on the United States? One study published in 2006 quotes 350,000 hospitalizations, 5 million office visits, 276,000 emergency department visits, and 234,000 urgent care visits per year due to atrial fibrillation. Total annual costs were estimated at $6.65 billion, with $2.93 billion (44%) for primary discharge diagnosis, $1.95 billion (29%) for incremental inpatient hospitalization costs as a comorbid diagnosis, $1.53 billion (23%) for outpatient treatment of atrial fibrillation, and $235 million (4%) for prescription drugs. 12 A cost evaluation in the province of Ontario, Canada, was recently published. Although the costs are based on Canadian dollars and care, the results were significantly in favor of LAA occlusion, with higher quality-adjusted life years and lower discounted lifetime costs compared to warfarin or dabigatran. 13 What is the impact of LAA closure on practice? This is tough to say because this will depend on a few factors. The first is the need to isolate the number of Figure 3. Relationship of the constrained devices and radiopaque sheath marker bands Boston Scientific Corporation or its affiliates. All rights reserved. Used with permission of Boston Scientific nonvalvular atrial fibrillation patients without another reason to be on oral anticoagulation therapy (eg, a patient with a mechanical valve, recurrent pulmonary embolism, or hypercoagulable disorder requiring lifelong warfarin). The second factor is whether this will be listed as a first-line therapy in comparison to oral anticoagulation or a second-line therapy to oral anticoagulation. Although European numbers may not be used as a direct comparison, European guidelines 5 gave IIb approval to patients who were not able to undergo anticoagulation. In contrast, the United States is seeking approval for patients who are candidates for anticoagulation. The third factor is how widespread LAA closure will be; this depends on how many interventional cardiologists, electrophysiologists, and hospital systems are capable of implementing this procedure. A fourth factor is the need for adequate reimbursement, which is discussed in the following section. REGULATION AND REIMBURSEMENT The United States regulations and reimbursement codes are still to be determined for the Watchman device; however, Boston Scientific may likely push for certain qualifications for a site to be ideally situated to start a Watchman program. This section primarily includes recommendations from Boston Scientific, but it is likely that the FDA and CMS official requirements may vary from these. The site will likely need a dedicated interventional/ heart team to support Watchman procedures. The personnel will include a coordinator, multispecialty implanting physician team (collaboration between elec- JULY/AUGUST 2014 CARDIAC INTERVENTIONS TODAY 79
4 trophysiology and interventional cardiology), dedicated echocardiographer who will attend formal implantation training, anesthesiology support, cardiac surgery backup, and consistent nurse/tech support with scrubbing in on all procedures. The implanting physicians should include at least one who has performed a significant number of interventional cardiac procedures requiring a transseptal puncture. The team would benefit from having experience and teamwork in performing other complex procedures, such as transcatheter aortic valve replacement, mitral valve interventions, and/or ablation procedures. There should also be adequate space to perform LAA closure in the cath lab/electrophysiology lab. There is a significant learning curve that accompanies LAA closure. Therefore, operators and teams should be capable of handling complications such as hematoma/ vascular injury, pericardial effusion/tamponade, and device embolization. Some complications happen or are recognized after the patient has left the lab; the receiving hospital unit should have the capacity to recognize and react to such issues emergently. From a reimbursement perspective, the Watchman LAA closure system has an associated code and payment. However, coverage will need to be defined when the device becomes commercially available. DRAWBACKS AND CHALLENGES One of the drawbacks to all LAA closure devices stems from issues related to the operator learning curve, including complication prevention and management. Possible complications are vascular access injury, transseptal puncture issues, air embolism (leading to stroke or myocardial infarction), device embolization, and also pericardial effusion/tamponade. Careful vigilance is needed to prevent these complications; it is important that the staff is ready and able to handle complications before they occur. The Watchman device also requires a significant anatomical depth prior to implantation. For small lobes or large shallow LAAs, the Watchman device may not be a feasible option. Other challenges include the appropriate followup period after implantation of the device. Current practice, as per the PROTECT-AF trial, is to continue anticoagulation with warfarin after the procedure until a 45-day follow-up TEE is performed. If there is no thrombus and seal is present (residual peridevice flow < 5 mm in width on TEE), warfarin is discontinued, and aspirin ( mg) and clopidogrel (75 mg) are given for a total of 6 months, after which, aspirin is continued indefinitely. If a leak or thrombus is seen, warfarin is continued. It is unclear as to how long warfarin should Figure 4. The Watchman 5 device (in development) Boston Scientific Corporation or its affiliates. All be continued in those circumstances when thrombus or a leak occurs. A substudy of the PROTECT-AF trial showed that 32% of patients had some peridevice flow at 12 months; however, this was not associated with a higher risk of thromboembolism (although there was a low overall event rate). 14 FUTURE DIRECTIONS The next-generation Watchman 5 device (Figure 4) has significant changes compared to the current Watchman device. There is a closed distal end, an expanded LAA treatment range, and enhanced sealing. The device is also capable of full recapture and redeployment, as with the previous generation. There are also other areas for expansion of United States indications. The device has been tested in patients who are not candidates for anticoagulation in the ASAP trial, 6 which showed that LAA closure with the Watchman device can be safely performed without a warfarin transition. For patients who cannot tolerate TEE, LAA closure procedures have been performed with intracardiac echocardiography. 15,16 Other areas of interest are in imaging for LAA closure. As previously mentioned, intracardiac echocardiography is being used in some centers for periprocedural imaging; the LAA procedure has been performed without general anesthesia. 16 CT imaging has also been used for thrombus exclusion and appendage sizing. 17,18 80 CARDIAC INTERVENTIONS TODAY JULY/AUGUST 2014
5 Further clinical studies are currently being conducted. An international registry called the Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION), is one such study collecting data. 19 This 45-center study is designed as an observational prospective cohort study that will follow patients for up to 2 years to describe procedural safety and long-term efficacy. The estimated enrollment is 1,000 patients. In addition, it is highly likely that the FDA will require a postapproval study as a condition of approval. CONCLUSION The burden of atrial fibrillation is significant in the United States population, especially due to the risk of overall and severe stroke. The Watchman LAA closure device is a proven device that reduces the occurrence of stroke in patients with nonvalvular atrial fibrillation. Approval is expected in 2014, with labeling still to be confirmed. Sites in the United States will most likely need to have a team that cooperatively recruits, discusses, treats, and follows patients together to be successful. Involvement in a postapproval study may also be required. This information will be very important for inclusion and advancement in the United States society guidelines for atrial fibrillation. Recently, the FDA requested an additional advisory panel review of the WATCHMAN trial data. At the time of this writing, the reasons for the third panel meeting are not clear. While FDA approval had been anticipated, it is clear that any further clarity about the status of US approval and commercialization will depend on the upcoming FDA review. n Sameer Gafoor, MD, is with the CardioVascular Center Frankfurt in Frankfurt, Germany. He stated that he has Luisa Heuer is with the CardioVascular Center Jennifer Franke, MD, is with the CardioVascular Center Frankfurt in Frankfurt, and the University of Heidelberg in Heidelberg, Germany. She stated that she has no financial interests related to this article. Markus Reinartz, MD, is with the CardioVascular Center Frankfurt in Frankfurt, Germany. He stated that he has Stefan Bertog, MD, is with the CardioVascular Center Frankfurt in Frankfurt, and the Minnesota Veterans Affairs Medical Center in Minneapolis, Minnesota. He stated that he has no financial interests related to this article. Laura Vaskelyte, MD, is with the CardioVascular Center Ilona Hofmann, MD, is with the CardioVascular Center Prof. Horst Sievert, MD, is with the CardioVascular Center Frankfurt in Frankfurt, Germany. He has disclosed that he has ownership interest in or has received consulting fees, travel expenses, or study honorariums from the following companies: Abbott, Access Closure, AGA, Angiomed, Arstasis, Atritech, Atrium, Avinger, Bard, Boston Scientific, Bridgepoint, Cardiac Dimensions, CardioKinetix, CardioMEMS, Coherex, Contego, CSI, EndoCross, EndoTex, Epitek, Evalve, ev3, FlowCardia, Gore, Guidant, Guided Delivery Systems, Inc., InSeal Medical, Lumen Biomedical, HLT, Kensey Nash, Kyoto Medical, Lifetech, Lutonix, Medinol, Medtronic, NDC, NMT, OAS, Occlutech, Osprey, Ovalis, Pathway, PendraCare, Percardia, pfm Medical, Rox Medical, Sadra, SJM, Sorin, Spectranetics, SquareOne, Trireme, TriVascular, Velocimed, and Veryan. Prof. Sievert may be reached at ; info@cvcfrankfurt.de. 1. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374: Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) clinical trial and the Continued Access registry. Circulation. 2011;123: Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial. Circulation. 2013;127: Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. J Am Coll Cardiol. 2014; DOI: /j.jacc Camm AJ, Lip GY, De Caterina R, et al focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33: Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61: Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114: Cotter PE, Martin PJ, Ring L, et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology. 2013;80: Winter Y, Wolfram C, Schaeg M, et al. Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol. 2009;256: Bruggenjurgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health. 2007;10: Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31: Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9: Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013;127: Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012;59: Ho IC, Neuzil P, Mraz T, et al. Use of intracardiac echocardiography to guide implantation of a left atrial appendage occlusion device (PLAATO). Heart Rhythm. 2007;4: Ronco F, Pascotto A, Barbierato M, Grassi G. Percutaneous left atrial appendage closure in awake non intubated patient: multimodality intraprocedural imaging. Cardiovasc Revasc Med. 2012;13: Nasis A, Mottram PM, Cameron JD, Seneviratne SK. Current and evolving clinical applications of multidetector cardiac CT in assessment of structural heart disease. Radiology. 2013;267: Wu X, Wang C, Zhang C, et al. Computed tomography for detecting left atrial thrombus: a meta-analysis. Arch Med Sci. 2012;8: ClinicalTrials.gov website. Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION). Accessed May 28, JULY/AUGUST 2014 CARDIAC INTERVENTIONS TODAY 81
Patients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationRole of Imaging in Complex LAA Closure Anatomies
Role of Imaging in Complex LAA Closure Anatomies Sameer Gafoor 1,2 1 Swedish Heart and Vascular: Ming Zhang, Paul Huang, Darryl Wells, Adam Zivin, John Petersen II, Madalena Petrescu, Nimish Muni, Eric
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationLeft atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationGauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationMy Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position
LINC 2016 Leipzig, Jan 26-29, 2016 My Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position Horst Sievert, Iris Grunwald CardioVasculäres Centrum Frankfurt - CVC, Frankfurt
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationEndocardial LAA Occlusion: Which Device for Which Patient?
Endocardial LAA Occlusion: Which Device for Which Patient? Roy Beinart, MD Davidai Arrhythmia Center The Leviev Heart Center Sheba Medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationChapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationTITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the
More informationIs there a role for transcatheter left atrial appendage occlusion?
REVIEW Review Is there a role for transcatheter left atrial appendage occlusion? For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationSURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES Dr. Marco Barbierato Interventional Cardiology Cardio-Thoraco-Vascular Department
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationAvoiding and Managing Complications During CAS: Lessons Learned
LINC 2019 Leipzig, Germany, Jan 22-25, 2019 Avoiding and Managing Complications During CAS: Lessons Learned Horst Sievert, Ilona Hofmann, Kolja Sievert, Laura Vaskelyte, Sameer Gafoor, Stefan Bertog, Predrag
More informationCommercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
More informationDevice-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review
CSE REPORT Iwona Świątkiewicz, Marek Woźnicki, dam Sukiennik, Jacek Kubica Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, ydgoszcz, Poland
More informationCase Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationLeft Atrial Appendage Closure: Neurological events
Left Atrial Appendage Closure: Neurological events Medical Director- Foundation for Cardiovascular Medicine San Diego, CA Director Advanced Interventional Therapies- Gagnon Cardiovascular Institute, Morristown,
More informationWhich System Is better?: Watchman or Cardiac Plug or Something Else?
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 Which System Is better?: Watchman or Cardiac Plug or Something Else? Horst Sievert, Annkathrin Brauth, Isabel Schulmeyer, Patrick Boehm, Jonas
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationDad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
More informationReview Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure with Transeosophageal Echocardiography Guidance
Hindawi Publishing Corporation rombosis Volume 2014, Article ID 832752, 6 pages http://dx.doi.org/10.1155/2014/832752 Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationWATCHMAN REIMBURSEMENT GUIDE. This comprehensive guide provides an overview of the coding, coverage and payment landscape for the WATCHMAN system.
WATCHMAN REIMBURSEMENT GUIDE This comprehensive guide provides an overview of the coding, coverage and payment landscape for the WATCHMAN system. For questions regarding WATCHMAN reimbursement, please
More informationWATCHMAN: Where do we stand
Latest Updated on LAAC and Its Clinical Evidence Saibal Kar, MD, FACC, FAHA, FSCAI Associate Professor Heart Institute, t Cedars Sinai i Medical Center, Los Angeles, CA Disclosure Information WATCHMAN:
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More informationDepartment of Neurology, Medical University of Silesia, Hospital No. 7, Professor Leszek Giec Upper Silesian Medical Centre, Katowice, Poland
Original paper Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy Anetta Lasek-Bal
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationPercutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD
Percutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD Fédération de Cardiologie Hôpital Henri Mondor Créteil Atrial Fibrillation is a major cause of Stroke
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationAtrial fibrillation (AF) is a common arrhythmia worldwide
Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography Yae Matsuo, MD;* Petr Neuzil, MD, PhD;* Jan Petru, MD; Milan
More informationThe Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation
Journal of the American College of Cardiology Vol. 59, No. 10, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.028
More informationLeft Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationPercutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine
2.02.26 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine Effective Date August 29, 2014 Subsection Cardiology Original Policy Date July 6,
More informationLeft Atrial Appendage Closure Techniques: 2015
Left Atrial Appendage Closure Techniques: 2015 Ramon Quesada, MD, FACP, FACC, FSCAI Medical Director, Interventional Cardiology & Cardiac Research Medical Director, Structural Heart and TAVR Program Baptist
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationAtrial fibrillation (AF) is the most common
Left Atrial Appendage Closure With the Watchman Device A review of trial results and clinical application. BY JAYANT KHITHA, MD, AND TANVIR K. BAJWA, MD Atrial fibrillation (AF) is the most common arrhythmia
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 12/2018 Origination: 1/2012 Next Review: 12/2019 Policy Blue Cross and
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
More informationAtrial fibrillation (AF) remains the most common
The Spectrum of Devices for Percutaneous Left Atrial Appendage Occlusion A look at current and emerging nonpharmacologic stroke prevention therapies. BY LLUIS ASMARATS, MD, AND JOSEP RODÉS-CABAU, MD Atrial
More informationPatent Foramen Ovale Closure With the SeptRx Device
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 9, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.04.019 Patent Foramen
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationLeft atrial appendage (LAA) closure is now a commercially
Assessing Anatomy for Left Atrial Appendage Closure The roles of TEE and CTA in anatomic assessment and device selection for LAA closure. BY DEE DEE WANG, MD, AND MARVIN H. ENG, MD Left atrial appendage
More informationPercutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationTransseptal catheterization is frequently performed to
The Incidence and Long-Term Clinical Outcome of Iatrogenic Atrial Septal Defects Secondary to Transseptal Catheterization With a 12F Transseptal Sheath Sheldon M. Singh, MD; Pamela S. Douglas, MD, MACC,
More information16th ANGIOPLASTY SUMMIT-TCTAP TCTAP 2011 Seoul, Korea, April 27 29, 2011 Left Atrial Appendage Closure State of the Art Horst Sievert, Nina Wunderlich, Maik Gonzaga, Annkathrin Braut, Ilona Hofmann CardioVascular
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
More informationLeft Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP
Left Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP Cardiac Electrophysiology Nurse Practitioner OhioHealth Heart & Vascular Physicians Riverside Methodist Hospital none Disclosures Atrial Fibrillation
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 10, NO. 21, 2017 ª 2017 PUBLISHED BY ELSEVIER ON BEHALF OF THE
ª 2017 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 http://dx.doi.org/10.1016/j.jcin.2017.06.072 STRUCTURAL: ATRIAL INTERVENTION FOCUS Percutaneous
More informationEAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
More informationUpdates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationNon-Pharmacologic Stroke Prevention For Atrial fibrillation: A Practical Review for the Practicing Cardiologist
Review articles A Journal of Cardiological Society of India, Kerala Chapter Non-Pharmacologic Stroke Prevention For Atrial fibrillation: A Practical Review for the Practicing Cardiologist a b c Srinivasa
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationCase Report Pulmonary Vein Compression After Implantation of a Left Atrial Appendage Occluder: Presentation and Discussion of a Case
194 Case Report Pulmonary Vein Compression After Implantation of a Left Atrial Appendage Occluder: Presentation and Discussion of a Case Maryam Ayati MD, Feifan Ouyang MD, KH Kuck MD Department of cardiology,
More informationUpdate in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More information